PubRank

Donna M Weber

Author PubWeight™ 32.72‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. Blood 2013 2.59
2 Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008 1.63
3 Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer 2011 1.61
4 Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Blood 2012 1.58
5 Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma. Am J Hematol 2005 1.47
6 Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma. Eur J Haematol 2009 1.45
7 A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide. Blood 2012 1.33
8 Multiple myeloma. J Natl Compr Canc Netw 2011 1.28
9 Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010 1.18
10 The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function. Cancer 2010 1.16
11 Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol 2010 1.14
12 Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation. Blood 2005 1.09
13 Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev 2010 1.04
14 Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 2011 1.03
15 Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma. Leuk Lymphoma 2011 1.01
16 Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma. Biol Blood Marrow Transplant 2009 1.00
17 Case 181: synovitis acne pustulosis hyperostosis osteitis (SAPHO) syndrome. Radiology 2012 0.95
18 Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br J Haematol 2011 0.95
19 Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 2008 0.93
20 Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant. Biol Blood Marrow Transplant 2007 0.93
21 Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw 2012 0.89
22 Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma. Am J Hematol 2012 0.86
23 Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma 2004 0.86
24 Primary cutaneous plasmacytoma. Cutis 2014 0.82
25 Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma. Eur J Haematol 2003 0.82
26 Nuclear BCL-10 expression is common in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia and does not correlate with p65 NF-kappaB activation. Mod Pathol 2006 0.77
27 Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications. Exp Hematol 2013 0.77
28 Novel agents for relapsed and/or refractory multiple myeloma. Cancer J 2009 0.76
29 Lenalidomide in multiple myeloma. Best Pract Res Clin Haematol 2007 0.76
30 The multiple oral presentations of multiple myeloma. Support Care Cancer 2013 0.76